| Depression, Bipolar
Caplyta vs Latuda
Side-by-side clinical, coverage, and cost comparison for depression, bipolar.Deep comparison between: Caplyta vs Latuda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLatuda has a higher rate of injection site reactions vs Caplyta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Latuda but not Caplyta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Caplyta
Latuda
At A Glance
Oral
Once daily
Atypical antipsychotic
Oral
Once daily
Atypical antipsychotic
Indications
- Schizophrenia
- Depression, Bipolar
- Major Depressive Disorder
- Schizophrenia
- Depression, Bipolar
Dosing
Schizophrenia, Depression, Bipolar, Major Depressive Disorder 42 mg orally once daily with or without food; no dose titration needed.
With strong CYP3A4 inhibitors Reduce to 10.5 mg once daily.
With moderate CYP3A4 inhibitors Reduce to 21 mg once daily.
Moderate or severe hepatic impairment Reduce to 21 mg once daily (Child-Pugh class B or C).
Schizophrenia Adults: 40 mg once daily (range 40-160 mg/day); adolescents 13-17 years: 40 mg once daily (range 40-80 mg/day); take with food (at least 350 calories).
Depression, Bipolar Adults: 20 mg once daily as monotherapy or adjunctive therapy with lithium or valproate (range 20-120 mg/day); pediatric patients 10-17 years: 20 mg once daily as monotherapy (range 20-80 mg/day); take with food (at least 350 calories).
Contraindications
- History of hypersensitivity reaction to lumateperone or any component of CAPLYTA (including pruritus, rash, and urticaria)
- Known hypersensitivity to lurasidone HCl or any components in the formulation
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)
- Concomitant use with strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine)
Adverse Reactions
Most common (>=5%) Somnolence/sedation, dizziness, nausea, dry mouth, headache, fatigue, diarrhea, vomiting
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, suicidal thoughts and behaviors, cerebrovascular adverse reactions including stroke in elderly patients with dementia-related psychosis
Postmarketing Burning sensation, including skin burning sensation
Most common (>=5%) Somnolence, akathisia, extrapyramidal symptoms, nausea, vomiting, diarrhea, anxiety
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, cerebrovascular adverse reactions, hyperprolactinemia, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, body temperature dysregulation
Postmarketing Urticaria, throat swelling, tongue swelling, dyspnea, rash, hyponatremia
Pharmacology
Lumateperone is an atypical antipsychotic whose mechanism may be mediated through antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors; it also has moderate SERT inhibitory activity and moderate binding affinity for dopamine D1, D4, and adrenergic alpha-1 receptors.
Lurasidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors and as a partial agonist at 5-HT1A receptors, with little affinity for histamine H1 or muscarinic M1 receptors; its efficacy in schizophrenia and bipolar depression may be mediated through combined D2 and 5-HT2A receptor antagonism.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Caplyta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (2/12)
Latuda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Caplyta
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (6/8)
Latuda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Caplyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Latuda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Schizophrenia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CaplytaView full Caplyta profile
LatudaView full Latuda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.